Brief: Ryvu Therapeutics Says Its Project Recommended For Funding By Poland's PARP
March 27 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* SAYS RYVU PROJECT RECOMMENDED FOR FUNDING BY POLISH AGENCY
FOR
ENTERPRISE DEVELOPMENT
* TOTAL VALUE OF PROJECT AT 39.2 MILLION ZLOTYS
* RECOMMENDED VALUE OF SUBSIDY AT 26.3 MILLION ZLOTYS
* ONCO PRIME PROJECT RELATED TO ANTICANCER THERAPY
Source text for Workspace: ID:nEM1bmJ9pa
Further company coverage: RVU.WA
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Q1 Net Loss 12.6 Million Zlotys
Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
Brief: Ryvu Therapeutics FY Net Loss At 101.2 Mln Zlotys
Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
Brief: Ryvu Therapeutics Signs Grant Agreement With Poland's NCBR For PERO Project